Status:
COMPLETED
Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Collaborating Sponsors:
Taipei City Hospital
Conditions:
Anemia
Inflammation
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The response of Continuous Erythropoietic Receptor Activator (CERA) with different dose interval and the survey for influence factors: We aim to evaluate a better clinical response which can be achie...
Detailed Description
We included HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly ...
Eligibility Criteria
Inclusion
- HD patients with stable hematocrit (between 30\~36%) under intravenous administration of CERA 100 μg once monthly for two months.
Exclusion
- HD patients were excluded due to active bleeding (major trauma, gastric ulcer bleeding, or surgery), blood transfusion or administration of additional erythropoietic stimulating agent (ESA) other than CERA within the follow-up period during the study perod of 6 months. People who discontinued CERA as their ESA were also excluded.
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT02232113
Start Date
February 1 2012
End Date
January 1 2013
Last Update
September 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan, 112